CLNS1A

Across TCGA pan-cancer cohorts, CLNS1A mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of CLNS1A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CLNS1A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CLNS1A is over-expressed in tumor, although a few such as OV and PDAC show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where CLNS1A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLNS1A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	+0.403	<.001	12	view →
COAD	Male	II,III,IV	+0.422	<.001	11	view →
LSCC	Male	II,III,IV	+0.457	<.001	8	view →
LUAD	All	II,III,IV	+0.180	<.001	5	view →
OV	All	All	−0.332	.037	2	view →
PDAC	Female	II,III,IV	−0.279	.028	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

CLNS1A–CCRCC

Open the CCRCC breakdown →